Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg ( DrugBank: Golimumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03669029 (ClinicalTrials.gov) | October 1, 2018 | 4/7/2018 | Optimization of Golimumab Treatment in Ulcerative Colitis | Optimization of Golimumab Treatment in Ulcerative Colitis | Colitis, Ulcerative | Drug: Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Drug: Golimumab treatment optimization. | Hospital de Manises | Valencia University General Hospital;Hospital Clínico Universitario de Valencia;Hospital de Sagunto;Hospital Universitario La Fe;Hospital General Universitario de Alicante;Hospital Universitario Doctor Peset;Hospital Arnau de Vilanova;Hospital Provincial de Castellon;Merck Sharp & Dohme Corp. | Unknown status | 18 Years | 80 Years | All | 50 | Phase 4 | Spain |